EA199700437A1 - Микроинкапсулированные лактобациллы для медицинского применения - Google Patents

Микроинкапсулированные лактобациллы для медицинского применения

Info

Publication number
EA199700437A1
EA199700437A1 EA199700437A EA199700437A EA199700437A1 EA 199700437 A1 EA199700437 A1 EA 199700437A1 EA 199700437 A EA199700437 A EA 199700437A EA 199700437 A EA199700437 A EA 199700437A EA 199700437 A1 EA199700437 A1 EA 199700437A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microincapsulated
lactobacilles
treat
medical application
prevent
Prior art date
Application number
EA199700437A
Other languages
English (en)
Other versions
EA000412B1 (ru
Inventor
Лэрри С. Форд
Original Assignee
Лэфор Лэбараторис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лэфор Лэбараторис Лимитед filed Critical Лэфор Лэбараторис Лимитед
Publication of EA199700437A1 publication Critical patent/EA199700437A1/ru
Publication of EA000412B1 publication Critical patent/EA000412B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Микроинкапсулированные лактобациллы вводят оральным путем млекопитающим, в том числе и людям, для лечения или предотвращения вызванной антибиотиками или других хронических или острых форм диареи. Микроинкапсулированные лактобациллы применяют местно, на коже, для лечения или предотвращения кожных инфекций или вводят интравагинально для лечения или предотвращения вагинальных заражений дрожжеподобными грибами.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700437A 1995-06-02 1996-05-31 Фармацевтические композиции, содержащие в качестве активного начала жизнеспособные лактобациллы, способы их применения и препарат из микроинкапсулированных лактобацилл EA000412B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/459,058 US5733568A (en) 1993-12-03 1995-06-02 Micro-encapsulated lactobacilli for medical applications
PCT/US1996/008260 WO1996038159A1 (en) 1995-06-02 1996-05-31 Micro-encapsulated lactobacilli for medical applications

Publications (2)

Publication Number Publication Date
EA199700437A1 true EA199700437A1 (ru) 1998-08-27
EA000412B1 EA000412B1 (ru) 1999-06-24

Family

ID=23823243

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700437A EA000412B1 (ru) 1995-06-02 1996-05-31 Фармацевтические композиции, содержащие в качестве активного начала жизнеспособные лактобациллы, способы их применения и препарат из микроинкапсулированных лактобацилл

Country Status (21)

Country Link
US (4) US5733568A (ru)
EP (1) EP0828499B1 (ru)
JP (1) JPH11506451A (ru)
KR (1) KR100478326B1 (ru)
CN (1) CN1100546C (ru)
AR (1) AR002754A1 (ru)
AT (1) ATE286737T1 (ru)
AU (1) AU702799B2 (ru)
BR (1) BR9609460A (ru)
CA (1) CA2222642C (ru)
DE (1) DE69634171T2 (ru)
EA (1) EA000412B1 (ru)
HU (1) HUP9900682A3 (ru)
IL (1) IL118304A (ru)
MX (1) MX9709318A (ru)
MY (1) MY120501A (ru)
NZ (1) NZ309456A (ru)
PL (1) PL323748A1 (ru)
TW (1) TW480174B (ru)
WO (1) WO1996038159A1 (ru)
ZA (1) ZA963810B (ru)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
GB2310375A (en) * 1996-02-21 1997-08-27 Vanessa Clare Mcclafferty Pessaries for treating vaginal infections
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
RO113114B1 (ro) * 1997-08-05 1998-04-30 Rodica Teodorescu Produs eubiotic natural, pentru intretinerea si tratamentul tegumentelor
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
DE69802260T2 (de) 1998-04-30 2002-07-04 Vesely Renata Maria Cavaliere Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
BR9916062A (pt) * 1998-12-11 2002-09-24 Urex Biotech Inc Administração oral de lactobacillus para o tratamento e prevenção de infecção urogenital
US20040197352A1 (en) * 1999-04-30 2004-10-07 Natarajan Ranganathan Methods of improving or augmenting kidney function
US6706287B2 (en) * 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
US7998470B2 (en) * 1999-04-30 2011-08-16 Kibow Biotech, Inc. Compositions and methods improving renal function
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1110555A1 (fr) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
US7206941B2 (en) * 2000-08-28 2007-04-17 Contentguard Holdings, Inc. Method and apparatus for validating security components through a request for content
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20050266069A1 (en) * 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
AU2004265511A1 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US7132102B2 (en) * 2003-08-21 2006-11-07 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
CA2540467C (en) 2003-09-30 2013-11-12 Kibow Biotech, Inc. Compositions and methods for augmenting kidney function
US20070009490A1 (en) * 2003-10-02 2007-01-11 Conte Anthony E Dried biotherapeutic composition, uses, and device and methods for administration thereof
WO2005034861A2 (en) * 2003-10-02 2005-04-21 The Bio Balance Corporation A dried biotherapeutic composition, uses, and device and methods for administration thereof
IE20030773A1 (en) 2003-10-17 2005-04-20 Teagasc Agric Food Dev Authori Use of probiotic bacteria in the treatment of infection
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050208034A1 (en) * 2004-03-17 2005-09-22 Jordan Lazonia V Natural vaginal yeast infection control
JP2008503563A (ja) * 2004-06-23 2008-02-07 ロレアル 敏感及び／又は乾燥肌の予防及び／又は処置に有用な方法及び組成物
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
AU2005291098B2 (en) * 2004-10-04 2011-11-24 L'oreal Cosmetic and/or dermatological composition for sensitive skins
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
CA2616443C (en) 2005-07-28 2017-10-10 University Of Hull Uses of sporopollenin as an antioxidant
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
CN100382792C (zh) * 2005-09-12 2008-04-23 大连三仪动物药品有限公司 药用水溶性微胶囊及生产方法
US20070166295A1 (en) * 2006-01-13 2007-07-19 Vet Solutions L.P. Anti-Diarrhea Preparations for Small Domestic Animals
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP1911358B1 (en) * 2006-10-13 2009-06-17 Compagnie Gervais Danone New composition for improving skin quality and a process for preparing the same
ES2551719T3 (es) 2007-02-01 2015-11-23 Iams Europe B.V. Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
ES2322116B1 (es) 2007-03-12 2010-03-29 Consejo Superior Investig. Cientificas Microorganismo productor de anticuerpos, elementos necesarios para su obtencion, anticuerpos asi producidos, composiciones terapeuticas y sus aplicaciones.
FR2919501B1 (fr) * 2007-08-02 2010-12-31 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
CA2697735C (en) * 2007-09-04 2014-02-18 L'oreal Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin
FR2920305B1 (fr) * 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
US8236297B2 (en) * 2007-10-11 2012-08-07 Kenneth Manzo Method of treating lactose intolerance using genetically engineered bacteria
WO2009123982A2 (en) * 2008-03-31 2009-10-08 Osel, Inc. Transiently buffered lactobacillus preparations and use thereof
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR100990765B1 (ko) 2008-06-13 2010-10-29 롯데쇼핑주식회사 락토바실러스 펜토서스 3090의 배양상등액을 함유하는항균제 조성물
GB0812513D0 (en) 2008-07-09 2008-08-13 Univ Hull Delivery vehicle
EP2158916A1 (en) * 2008-08-27 2010-03-03 Ellen Aktiebolag Administration unit comprising lactic acid bacteria
FR2942719B1 (fr) * 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
CL2009001505A1 (es) * 2009-07-01 2009-09-25 Univ Concepcion Formulacion prebiotica de uso topico que comprende microesferas con composicion matricial a base de gelatina natural reticulada y una cepa probiotica viable de lactobacillus spp; proceso para generar dicha formulacion; uso de dicha formulacion para tratar lesiones de la piel.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
US20110070334A1 (en) 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
PT2338476E (pt) * 2009-12-02 2012-09-28 Bettina Heil Supositório para administração rectal, vaginal ou uretral contendo um probiótico, um antibiótico e um ácido adiposo insaturado não esterificado
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
NL2004520C2 (en) * 2010-04-07 2011-10-11 Univ Delft Tech HEALING AGENT FOR SELF-HEALING CEMENTIOUS MATERIALS.
MY175316A (en) 2011-01-25 2020-06-19 Austrianova Singapore Pte Ltd Protection of microbial cells from acidic degradation
DE102011009798B4 (de) 2011-01-31 2015-03-05 Merz Pharma Gmbh & Co. Kgaa Balneologische lipidhaltige probiotische Zubereitungen für kosmetische / dermatologische / medizinische Anwendungen
CN104302278B (zh) 2012-03-29 2018-08-21 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
CN102613458B (zh) * 2012-04-16 2013-12-18 广东仙乐制药有限公司 一种益生菌软胶囊及其制备方法
WO2013171515A1 (en) 2012-05-18 2013-11-21 Genome Research Limited Methods and groups
FR2999601B1 (fr) 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
CN105120847B (zh) 2013-03-14 2018-12-28 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
KR101640744B1 (ko) 2014-05-07 2016-07-19 일동제약주식회사 고분자 다당 바인더에 컨쥬게이트된 락토바실러스 람노서스 rht-3201, 및 이의 아토피 예방 및 치료 용도
US10632157B2 (en) 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
MX2017016924A (es) 2015-06-25 2018-08-15 Ascus Biosciences Inc Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e indentificar sus relaciones funcionales e interacciones y seleccionar y sintetizar conjuntos microbianos basados en estos.
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10588926B2 (en) * 2015-06-29 2020-03-17 Ferring B.V. Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis
BR112018013975A2 (pt) 2016-01-07 2019-02-05 Ascus Biosciences Inc métodos para melhoria da produção de leite por administração de consórcios microbianos
MX2018012553A (es) 2016-04-15 2019-03-28 Ascus Biosciences Inc Metodos para mejorar la produccion agricola de aves de corral mediante la administracion de consorcios microbianos o cepas purificadas de los mismos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3562954A1 (en) 2016-12-28 2019-11-06 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
UY37708A (es) 2017-04-28 2018-10-31 Ascus Biosciences Inc Métodos para complementar dietas con alto consumo de granos y/o alto valor energético en rumiantes, mediante la administración de un bioensamble sintético de microbios, o cepas purificadas de los mismos
CN111970933A (zh) 2017-10-18 2020-11-20 埃斯库斯生物科技股份公司 通过施用微生物或其纯化菌株的合成生物集合体来提高禽类产量
RU2744839C1 (ru) * 2020-02-02 2021-03-16 Михаил Викторович Комаров Микроконтейнеры для защиты микроорганизмов, применяемые в сельском хозяйстве

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4983163A (en) * 1981-10-09 1991-01-08 Science Research Center, Inc. Method, compositions and articles for prevention and treatment of herpes simplex virus infections
JPS5911177A (ja) * 1982-07-12 1984-01-20 Seikenkai 新規乳酸桿菌
CN1057446C (zh) * 1993-02-02 2000-10-18 西安华誉技术发展有限公司 活性乳酸杆菌胶囊
ZA942302B (en) * 1993-12-03 1995-09-29 Lafor Lab Ltd Viracidal bactericidal and spermicidal vaginal suppository
UA39965C2 (uk) * 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )

Also Published As

Publication number Publication date
MX9709318A (es) 1998-02-28
US5614209B1 (en) 1998-08-04
AR002754A1 (es) 1998-04-29
CN1100546C (zh) 2003-02-05
IL118304A0 (en) 1996-09-12
ATE286737T1 (de) 2005-01-15
WO1996038159A1 (en) 1996-12-05
CA2222642A1 (en) 1996-12-05
IL118304A (en) 2000-08-13
KR19990022220A (ko) 1999-03-25
EA000412B1 (ru) 1999-06-24
JPH11506451A (ja) 1999-06-08
NZ309456A (en) 2001-02-23
HUP9900682A2 (hu) 1999-06-28
AU702799B2 (en) 1999-03-04
US5635202A (en) 1997-06-03
EP0828499A1 (en) 1998-03-18
US5614209A (en) 1997-03-25
KR100478326B1 (ko) 2005-07-28
CA2222642C (en) 2004-09-07
HUP9900682A3 (en) 2000-10-30
PL323748A1 (en) 1998-04-14
AU5963196A (en) 1996-12-18
BR9609460A (pt) 1999-03-02
ZA963810B (en) 1997-01-03
DE69634171T2 (de) 2006-01-19
EP0828499B1 (en) 2005-01-12
DE69634171D1 (de) 2005-02-17
MY120501A (en) 2005-11-30
US5633012A (en) 1997-05-27
CN1192151A (zh) 1998-09-02
US5733568A (en) 1998-03-31
TW480174B (en) 2002-03-21

Similar Documents

Publication Publication Date Title
EA199700437A1 (ru) Микроинкапсулированные лактобациллы для медицинского применения
AU2310088A (en) Hemorrhoidal, other compositions and methods of treatment
RU94045285A (ru) Композиция против угрей с одновременным лечением поверхностных и глубоких слоев кожи и ее применение
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2132227T3 (es) Procedimiento y composicion para el cuidado de la piel.
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
WO1997015300A3 (de) Verwendung von 4-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
FR2695714B1 (fr) Installation de traitement cryogénique, notamment de distillation d'air.
RS20070379A (en) Pharmaceutical compositions of tizoxanide and nitazoxide
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
ES2193246T3 (es) Cefalosporinas antibacterianas.
TR199900505T2 (ru)
NO984760D0 (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
AU4726797A (en) Prophylactic/remedial agent
ES2093257T3 (es) Utilizacion de torasemida para la preparacion de medicamentos destinados al tratamiento de edemas cerebrales.
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
ES2159294T3 (es) Metodo y composicion para el tratamiento de la caida del cabello.
ITRM950180V0 (it) Allestimenti per lo svolgimento del gioco "wormhole action match".
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
ES2128353T3 (es) Composicion topica que contiene penciclovir.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
PT690715E (pt) Aplicacao topica e sistemica de buspirona ou seus derivados para tratamento de condicoes patologicas associadas a respostas imunitarias

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU